Published in J Med Chem on December 12, 2012
Sirtuin inhibitors as anticancer agents. Future Med Chem (2014) 0.98
Augmenting antitumor immune responses with epigenetic modifying agents. Front Immunol (2015) 0.98
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell (2016) 0.88
Chemical metabolic inhibitors for the treatment of blood-borne cancers. Anticancer Agents Med Chem (2014) 0.87
Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors. Eur J Med Chem (2014) 0.82
Characterization of Trypanosoma cruzi Sirtuins as Possible Drug Targets for Chagas Disease. Antimicrob Agents Chemother (2015) 0.81
Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem (2014) 0.81
Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics (2016) 0.80
SIRT2 is an unfavorable prognostic biomarker in patients with acute myeloid leukemia. Sci Rep (2016) 0.78
Evaluation of benzoic acid derivatives as sirtuin inhibitors. Bioorg Med Chem Lett (2013) 0.78
SIRT1 inhibition affects angiogenic properties of human MSCs. Biomed Res Int (2014) 0.77
The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer. Cell Rep (2016) 0.75
Sirtuin inhibitor sirtinol is an intracellular iron chelator. Chem Commun (Camb) (2015) 0.75
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget (2016) 0.75
Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, "selectivity pocket" and NAD(+)-binding site. Chem Sci (2017) 0.75
Sirtuins at the crossroads of stemness, aging, and cancer. Aging Cell (2017) 0.75
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A (2005) 15.46
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics (2011) 7.38
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci (2003) 6.24
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol (2006) 4.38
A role for RNAi in the selective correction of DNA methylation defects. Science (2009) 4.30
Distinct DNA methylomes of newborns and centenarians. Proc Natl Acad Sci U S A (2012) 4.26
Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol (2004) 4.15
Retracted A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet (2009) 3.88
Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res (2009) 3.81
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
DNA methylation and cancer. Adv Genet (2010) 3.50
Epigenetics and aging: the targets and the marks. Trends Genet (2007) 3.44
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci U S A (2004) 3.27
BLUEPRINT to decode the epigenetic signature written in blood. Nat Biotechnol (2012) 3.24
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol (2009) 3.05
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology (2008) 2.91
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell (2010) 2.89
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell (2010) 2.86
A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell (2010) 2.78
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
DNA methylation: a profile of methods and applications. Biotechniques (2002) 2.74
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
The role of histone deacetylases (HDACs) in human cancer. Mol Oncol (2007) 2.72
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med (2004) 2.71
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res (2007) 2.60
Notch signaling is essential for ventricular chamber development. Dev Cell (2007) 2.53
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res (2008) 2.52
The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development (2002) 2.50
PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell (2010) 2.50
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Res (2003) 2.41
Allele-specific histone lysine methylation marks regulatory regions at imprinted mouse genes. EMBO J (2002) 2.40
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet (2006) 2.33
Whole-genome bisulfite sequencing of two distinct interconvertible DNA methylomes of mouse embryonic stem cells. Cell Stem Cell (2013) 2.32
Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol (2005) 2.27
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol (2010) 2.25
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J (2007) 2.21
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21
A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics (2009) 2.21
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Cross-talk between aging and cancer: the epigenetic language. Ann N Y Acad Sci (2007) 2.17
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res (2006) 2.15
CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle (2007) 2.12
Cancer epigenomics: beyond genomics. Curr Opin Genet Dev (2012) 2.11
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem (2008) 2.09
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep (2007) 2.01
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet (2003) 1.93
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res (2004) 1.92
Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov (2007) 1.91
The role of epigenetics in aging and age-related diseases. Ageing Res Rev (2009) 1.89
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
DNA methylation polymorphisms precede any histological sign of atherosclerosis in mice lacking apolipoprotein E. J Biol Chem (2004) 1.82
Methyl-DNA immunoprecipitation (MeDIP): hunting down the DNA methylome. Biotechniques (2008) 1.81
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci U S A (2008) 1.80
A randomized prospective trial to assess the impact of transurethral resection in narrow band imaging modality on non-muscle-invasive bladder cancer recurrence. Eur Urol (2012) 1.79
Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett (2010) 1.79
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle-specific gene transcription. EMBO J (2005) 1.76
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol (2005) 1.74
Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol (2012) 1.73
Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res (2010) 1.73
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer (2004) 1.72
Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. Cancer Res (2007) 1.71
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A (2006) 1.70
Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res (2004) 1.66
DNA methylation contributes to natural human variation. Genome Res (2013) 1.66
Epigenetic disruption of the PIWI pathway in human spermatogenic disorders. PLoS One (2012) 1.64
Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment. Genome Res (2014) 1.64